• KOL
    • Overactive Bladder
    • Linda D Cardozo
    • Linda D Cardozo: Influence Statistics

      Linda D Cardozo

      Linda D Cardozo

      Show email address

      King's College Hospital NHS Foundation Trust, Department of Obstetrics and Gynaecology, Denmark Hill, Brixton, London SE5 9RS | Department of Obstetrics and Gynecology, King's ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Linda D Cardozo:Expert Impact

      Concepts for whichLinda D Cardozohas direct influence:Overactive bladder,Urinary incontinence,Detrusor overactivity,Detrusor instability,Stress incontinence,Urogenital prolapse,Urinary tract,Ambulatory urodynamics.

      Linda D Cardozo:KOL impact

      Concepts related to the work of other authors for whichfor which Linda D Cardozo has influence:Urinary incontinence,Overactive bladder,Pelvic floor,Quality life,Detrusor overactivity,Postmenopausal women,Sexual function.

      KOL Resume for Linda D Cardozo

      Year
      2022

      King's College Hospital NHS Foundation Trust, Department of Obstetrics and Gynaecology, Denmark Hill, Brixton, London SE5 9RS

      2021

      Department of Urogynaecology, King's College Hospital, London, UK.

      2020

      King′s College Hospital, London, England

      Department of Urogynaecology, Suite 8, Golden Jubilee Wing, King's College Hospital, London SE5 9RS, UK

      2019

      Department of Urogynaecology, Kings College Hospital, Denmark Hill, Camberwell, SE5 9RS, London, UK

      Kings College Hospital, London SE5 9RS, United Kingdom.

      2018

      King's College Hospital, London, UK

      Department of Urogynaecology, Kings College Hospital, London, United Kingdom

      2017

      King's College Hospital LondonEngland

      Department Of Urogynaecology, Kings College Hospital, United Kingdom

      King’s College Hospital, Denmark Hill, SE5 9RS, London, UK

      2016

      King's College Hospital London UK

      2015

      King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom

      Department of Urogynaecology, King’s College Hospital NHS Foundation Trust, Denmark Hill, SE5 9RS, London, UK

      2014

      Linda Cardozo MD FRCOG is Professor of Urogynaecology at King's College Hospital, London, UK. Conflicts of interest: none declared

      Department of Urogynaecology, King's College Hospital NHS Foundation Trust, London,

      Pinner Middlesex United Kingdom

      2013

      Department of Urogynaecology, King’s College Hospital, SE5 9RS, London, UK

      2012

      Linda Cardozo MD FRCOG is Professor of Urogynaecology at King’s College Hospital, London, UK. Conflicts of interest: none declared

      Department of Urogynaecology, King's College Hospital, Denmark Hill, London SE5 9RS, Subspecialty Trainee in Urogynaecology, Department of Urogynaecology, King's College Hospital, Denmark Hill, SE5 9RS London, United Kingdom

      Kings College Hospital, UK

      2011

      Kings College Hospital, United Kingdom

      King's College Hospital, Subspecialty trainee in Urogynaecology, Suite 8 Golden Jubilee Wing, Denmark Hill London SE5 9 RS, UK

      2010

      Department of Urogynaecology, King’s College Hospital, London UK

      King's College London,

      2009

      Professor of Urogynaecology, Suite 8, Golden Jubilee Wing, King’s College Hospital, Denmark Hill, London, SE5 9RS, UK.

      Department of Urogynaecology, King’s College Hospital, University of London, London, UK

      Kings College London, Denmark Hill, London SE5 9RS, United Kingdom

      2008

      Department of Urogynaecology, King's College Hospital, University of London, UK

      Kings College Hospital, London,

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Linda D Cardozo is among the top experts in the world.
      Concept World rank
      validated questionnaires urgency #1
      elderly women year #1
      symptom complex urgency #1
      labiaplasty #1
      thermal therapy lutd #1
      tolenix #1
      central reviewers icc #1
      assessment urinary symptoms #1
      women bjhs #1
      absst women #1
      procedure tvt #1
      medium term analysis #1
      lutd oab #1
      foreign material methods #1
      severity usi #1
      ici‐rs 2014 #1
      score burden score #1
      trospium chloride tcl #1
      nonstandardised terminology #1
      morphology hiatal area #1
      prolapse impact life #1
      symptoms analysis #1
      urinary bladder phase #1
      evidence urogenital effects #1
      women diary #1
      tufs oab #1
      symptoms acceptability #1
      international multi‐center #1
      women fcgs #1
      uds children #1
      real burden #1
      slings excellent #1
      rates treatment discontinuation #1
      excellent complications #1
      6 mths–40 years #1
      antimuscarinics synergistic #1
      week suboptimal #1
      stress profile parameters #1
      pqol bjhs #1
      ici‐rs 2019 proposal #1
      obstetric bladder #1
      urethral function stress #1
      rate antimuscarinics #1
      baseline incidence urgency #1
      placebo mui #1
      ici‐rs 2019 #1
      delivery urethral #1
      concept study efficacy #1
      bsug items #1
      acceptability symptoms #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Linda D Cardozo

      KOL-Index: 18224

      AIMS: Mirabegron, the first β3 -adrenoceptor agonist to enter clinical practice, has a different mechanism of action from antimuscarinic agents. This review presents data on the efficacy, safety, and tolerability of mirabegron in studies conducted to date.

      METHODS: All clinical data on mirabegron that are currently in the public domain are included, including some in-press manuscripts.

      RESULTS: In Phase III clinical trials in patients with overactive bladder (OAB), mirabegron at daily ...

      Known for Overactive Bladder | Oab Mirabegron | 12 Months | Urgency Incontinence | Efficacy Safety
      KOL-Index: 17236

      OBJECTIVE: To examine safety and tolerability findings as primary endpoints, and efficacy outcomes as secondary endpoints, of solifenacin treatment over a period of up to 1 year. Long-term efficacy in the treatment of overactive bladder (OAB) syndrome depends in part on the patient's persistence with pharmacologic therapy. Agents with a favourable therapeutic index supporting high levels of patient satisfaction and persistence are needed.

      METHODS: The present study was a 40-week ...

      Known for Solifenacin Treatment | Patients Oab | Overactive Bladder Syndrome | Persistence Therapy | Tolerability Efficacy
      KOL-Index: 16516

      PURPOSE: In this phase 3 trial we assessed the efficacy of solifenacin 5 mg and 10 mg daily in patients with symptoms related to overactive bladder. In addition, we assessed the safety and acceptability of solifenacin.

      MATERIALS AND METHODS: The study was a multicenter, multinational, randomized, double-blind, placebo controlled trial. Patients were randomized to 12-week once daily treatment with solifenacin 5 mg, solifenacin 10 mg or placebo. The primary efficacy variable was changed ...

      Known for Overactive Bladder | Solifenacin 5 | 24 Hours | Incontinence Episodes | Dry Mouth
      KOL-Index: 14805

      OBJECTIVE: To assess the effect of solifenacin succinate treatment on quality of life (QoL) measured in clinical trials in patients with overactive bladder (OAB).

      PATIENTS AND METHODS: QoL data using the King's Health Questionnaire (KHQ) were analysed from two phase-3, 12-week studies (1984 patients) and a long-term extension of these studies (1637 patients) where patients received solifenacin for up to an additional 40 weeks (i.e. a 52-week exposure to solifenacin). The 12-week studies ...

      Known for Qol Patients | Improved Quality | Placebo Solifenacin | Overactive Bladder Symptoms | Efficacy Tolerability
      KOL-Index: 14431

      AIMS: In this review we try to shed light on the following questions: *How frequently are symptoms of overactive bladder (OAB) and is detrusor overactivity (DO) present in patients with pelvic organ prolapse (POP) and is there a difference from women without POP? *Does the presence of OAB symptoms depend on the prolapsed compartment and/or stage of the prolapse? *What is the possible pathophysiology of OAB in POP? *Do OAB symptoms and DO change after conservative or surgical treatment of ...

      Known for Oab Symptoms | Overactive Bladder | Pelvic Organ | Patients Pop | Prolapse Surgery
      KOL-Index: 14334

      OBJECTIVE: To understand the pathophysiological mechanism of incontinence during orgasm and to compare women affected by symptomatic detrusor overactivity (DO) with and without incontinence at orgasm in terms of efficacy of antimuscarinic treatment.

      METHODS: All consecutive sexually active women with incontinence during intercourse were prospectively included and divided into two groups: women with coital incontinence at orgasm or at penetration. The two forms of coital incontinence were ...

      Known for Urinary Incontinence | Detrusor Overactivity | Orgasm Women | Antimuscarinic Treatment | Terms Efficacy
      KOL-Index: 13940

      INTRODUCTION: mirabegron is a β3-adrenoceptor agonist developed for the treatment of symptoms of overactive bladder (OAB). As the prevalence of OAB increases with age, a prospective subanalysis of individual and pooled efficacy and tolerability data from three 12-week, randomised, Phase III trials, and of tolerability data from a 1-year safety trial were conducted in order to evaluate the efficacy and tolerability of mirabegron in subgroups of patients aged ≥65 and ≥75 years.

      METHODS: ...

      Known for Overactive Bladder | Tolerability Mirabegron | 12 Weeks | 1 Year | Adrenoceptor Agonist
      KOL-Index: 13424

      OBJECTIVES: To design and validate a condition-specific quality of life questionnaire for the assessment of women with urinary incontinence, and to use the questionnaire to assess the quality of life of women with specific urodynamic diagnoses.

      SETTING: A tertiary referral urogynaecology unit at King's College Hospital, London.

      DESIGN: The questionnaire was designed following six different pilot studies; in this study it was tested for validity and reliability using standard psychometric ...

      Known for Life Women | New Questionnaire | Urinary Incontinence | Assessment Quality | Internal Consistency
      KOL-Index: 13083

      OBJECTIVE: To compare patient goal achievement in prolapse and continence surgery with objective/subjective outcomes; secondarily, to compare patient goal achievement with overall satisfaction and with that of the surgeon.

      DESIGN: Prospective longitudinal observational study, over 2 years.

      SETTING: Tertiary urogynaecology centre.

      POPULATION: Women with prolapse or stress incontinence due for surgery.

      METHODS: Patients and surgeons listed five goals that they hoped to achieve following ...

      Known for Goal Achievement | Satisfaction Surgeons | Pelvic Organ | Prolapse Surgery | Incontinence Stress
      KOL-Index: 12965

      BACKGROUND: Mirabegron, a β3-adrenoreceptor agonist, is an alternative drug to antimuscarinics for overactive bladder (OAB) symptoms.

      OBJECTIVE: To summarise safety and efficacy reporting of mirabegron treatment for OAB symptoms.

      DESIGN, SETTING, AND PARTICIPANTS: Pooled data analysed from 10 phase 2-4, double-blind, 12-wk mirabegron monotherapy studies in adults with OAB who had received one or more doses of study drug.

      INTERVENTION: Mirabegron: 25 and 50mg; antimuscarinics: solifenacin ...

      Known for Overactive Bladder | Efficacy Mirabegron | Oab Symptoms | Receptor Agonists | Outcome Urinary
      KOL-Index: 12931

      OBJECTIVES: To determine whether baseline urgency urinary incontinence (UUI) episodes predict the need for increased doses of fesoterodine in patients with overactive bladder (OAB), as clinicians would benefit from data that help to predict which patients require higher doses of antimuscarinics to manage UUI episodes.

      PATIENTS AND METHODS: In this pooled analysis of data from two double-blind, placebo-controlled trials, patients were randomized to placebo or fesoterodine 4 or 8 mg for 12 ...

      Known for Overactive Bladder | Fesoterodine Patients | Uui Episodes | Urinary Incontinence | 4 8
      KOL-Index: 12595

      Objectives:To determine whether the onset and duration of being overweight or obese are associated with symptoms of urinary incontinence.Design:Nationally representative cohort study.Subjects:A total of 1201 women followed-up since their birth in 1946 and annually from 48 to 54 years.Measurements:The body mass index (BMI) at the age of 20, 26, 36 and 43, and symptoms of stress, urge and severe incontinence at seven consecutive years from age 48 to 54.Results:In each year from age 48 to ...

      Known for Urinary Incontinence | Bmi Symptoms | British Prospective Cohort | Women Age | Stress Urge
      KOL-Index: 12441

      Introduction and hypothesisThis study evaluated the efficacy and safety of flexible-dose fesoterodine and factors associated with dose escalation in subjects with overactive bladder (OAB).MethodsIn this 12-week, open-label study, 331 adults with OAB symptoms for ≥3 months, ≥8 micturitions and ≥3 urgency episodes per 24 h and who reported at least “some moderate” bladder-related problems were treated with fesoterodine 4 mg once daily for 4 weeks, with the option to escalate to 8 mg for ...

      Known for Dose Escalation | Overactive Bladder | Baseline Week | Efficacy Safety | Fesoterodine 4
      KOL-Index: 12269

      OBJECTIVES: To conduct a systematic review to determine whether there is an association between metabolic syndrome (MetS) and lower urinary tract symptoms (LUTS) or overactive bladder (OAB) in women.

      METHODS: We systematically reviewed English language observational studies on the effect of MetS (or component factors) on the presence of OAB or LUTS in women. We searched PubMed, Web of Science and The Cochrane Library with no date restrictions, checked reference lists and undertook ...

      Known for Metabolic Syndrome | Overactive Bladder | Oab Women | Urinary Symptoms | Cardiovascular Risk

      Key People For Overactive Bladder

      Top KOLs in the world
      #1
      Paul H Abrams
      overactive bladder urinary incontinence international consultation
      #2
      Alan J Wein
      urinary bladder prostate cancer smooth muscle
      #3
      Linda D Cardozo
      overactive bladder urinary incontinence detrusor instability
      #4
      Philip E V A Van Kerrebroeck
      sacral neuromodulation overactive bladder urinary tract
      #5
      Ian Milsom
      urinary incontinence overactive bladder united states
      #6
      Christopher R Chapple
      overactive bladder urinary incontinence benign prostatic hyperplasia

      King's College Hospital NHS Foundation Trust, Department of Obstetrics and Gynaecology, Denmark Hill, Brixton, London SE5 9RS | Department of Obstetrics and Gynecology, King's College Hospital NHS Foundation Trust, Brixton, London, UK | Department of

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.